UGOLOTTI, MARTINA
 Distribuzione geografica
Continente #
AS - Asia 97
NA - Nord America 58
EU - Europa 54
SA - Sud America 13
AF - Africa 2
Totale 224
Nazione #
US - Stati Uniti d'America 58
SG - Singapore 41
IT - Italia 34
CN - Cina 25
BR - Brasile 9
VN - Vietnam 8
DE - Germania 7
HK - Hong Kong 7
RU - Federazione Russa 4
GB - Regno Unito 3
IN - India 3
IQ - Iraq 3
TR - Turchia 3
AR - Argentina 2
IE - Irlanda 2
KR - Corea 2
KZ - Kazakistan 2
NL - Olanda 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CL - Cile 1
EC - Ecuador 1
EG - Egitto 1
FR - Francia 1
JO - Giordania 1
PL - Polonia 1
ZA - Sudafrica 1
Totale 224
Città #
Ashburn 17
Singapore 16
Dallas 10
Parma 10
Hefei 8
Boardman 7
Hong Kong 7
Beijing 5
Milan 5
Ho Chi Minh City 4
Los Angeles 4
Istanbul 3
Munich 3
Berlin 2
Brooklyn 2
Buffalo 2
Dublin 2
Frankfurt am Main 2
Hanoi 2
New York 2
Piscataway 2
Seoul 2
São Paulo 2
Taiyuan 2
Verona 2
Almaty 1
Amman 1
Amsterdam 1
As Samawah 1
Baronissi 1
Bengaluru 1
Boston 1
Cairo 1
Canoas 1
Chennai 1
Curitiba 1
Guangzhou 1
Helena 1
Irecê 1
Jaboticabal 1
Jiaxing 1
Johannesburg 1
Karaganda 1
London 1
Moscow 1
Mosul 1
Mumbai 1
North Bergen 1
Oklahoma City 1
Paris 1
Poplar 1
Rosario 1
San Miguel de Tucumán 1
Santa Bárbara do Pará 1
Santa Clara 1
Shanghai 1
Sóc Trăng 1
Villarrica 1
Warsaw 1
Totale 157
Nome #
Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9 96
“Investigating PCSK9 inhibition as potential strategy in Alzheimer’s disease” 28
Mechanisms, Mediators, and Pharmacological Approaches Targeting Brain Cholesterol Transport in Alzheimer's Disease 21
"Effect of natural and synthetic PCSK9 inhibitors on Alzheimer’s disease-related parameters in human cerebral cell models" 21
In vitro and in vivo studies on novel PCSK9 inhibitors as pharmacological approach for the treatment of Alzheimer’s disease 15
“Studi in vitro e in vivo per lo sviluppo di nuovi inibitori di PCSK9 come strategia terapeutica nella malattia di Alzheimer” 14
“Proprotein convertase subtilisin/kexin type 9 and plasma/cerebrospinal fluid lipids in patients with cognitive decline” 14
“Probing the efficacy of natural and novel synthetic PCSK9 inhibitors in reducing neuroinlfammation, Aβ-induced neurotoxicity and modulating cholesterol uptake in human cerebral cell models” 13
“PCSK9 inhibition as potential strategy to treat Alzheimer’s disease: in vitro and in vivo studies” 13
Totale 235
Categoria #
all - tutte 607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 607


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202534 0 0 0 0 0 0 0 0 11 5 2 16
2025/2026201 6 16 17 11 95 56 0 0 0 0 0 0
Totale 235